Eculizumab is a humanized monoclonal antibody that has changed the natural history of aHUS; eculizumab acts by blocking terminal complement activation through inhibiting cleavage of complement C5 and was approved for the treatment of aHUS in 2011 [2, 3, 4, 5]. The gene discussed is C5; the disease is atypical hemolytic-uremic syndrome.